WallStSmart

Cencora Inc. (COR)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cencora Inc. generates 10498% more annual revenue ($325.78B vs $3.07B). COR leads profitability with a 50.0% profit margin vs 16.1%. COR appears more attractively valued with a PEG of 0.78. COR earns a higher WallStSmart Score of 62/100 (C+).

COR

Buy

62

out of 100

Grade: C+

Growth: 6.7Profit: 9.0Value: 7.3Quality: 5.0

WST

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 8.0Value: 4.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CORSignificantly Overvalued (-44.2%)

Margin of Safety

-44.2%

Fair Value

$253.59

Current Price

$325.08

$71.49 premium

UndervaluedFair: $253.59Overvalued
WSTSignificantly Overvalued (-256.8%)

Margin of Safety

-256.8%

Fair Value

$68.99

Current Price

$247.02

$178.03 premium

UndervaluedFair: $68.99Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COR5 strengths · Avg: 9.4/10
Return on EquityProfitability
133.5%10/10

Every $100 of equity generates 134 in profit

Profit MarginProfitability
50.0%10/10

Keeps 50 of every $100 in revenue as profit

Operating MarginProfitability
118.0%10/10

Strong operational efficiency at 118.0%

Market CapQuality
$63.24B9/10

Large-cap with strong market position

PEG RatioValuation
0.788/10

Growing faster than its price suggests

WST2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Areas to Watch

COR3 concerns · Avg: 2.7/10
P/E RatioValuation
39.1x4/10

Premium valuation, high expectations priced in

Price/BookValuation
33.1x2/10

Trading at 33.1x book value

Free Cash FlowQuality
$-2.42B2/10

Negative free cash flow — burning cash

WST3 concerns · Avg: 3.3/10
P/E RatioValuation
36.1x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
2.1%4/10

2.1% earnings growth

PEG RatioValuation
2.892/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : COR

The strongest argument for COR centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 50.0% and operating margin at 118.0%. PEG of 0.78 suggests the stock is reasonably priced for its growth.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.

Bear Case : COR

The primary concerns for COR are P/E Ratio, Price/Book, Free Cash Flow.

Bear Case : WST

The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.

Key Dynamics to Monitor

WST carries more volatility with a beta of 1.18 — expect wider price swings.

WST is growing revenue faster at 7.5% — sustainability is the question.

WST generates stronger free cash flow (175M), providing more financial flexibility.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

COR scores higher overall (62/100 vs 55/100), backed by strong 50.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cencora Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?